Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

(2016) Gregory J. Dore et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

(2016) Jason Grebely et al.   CLINICAL INFECTIOUS DISEASES

Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis

(2016) Bryony Simmons et al.   CLINICAL INFECTIOUS DISEASES

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine

(2015) Jacob Lalezari et al.   JOURNAL OF HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2015

(2015)   JOURNAL OF HEPATOLOGY

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

(2015) Graham R. Foster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

(2015) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis

(2013) Esther J. Aspinall et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology and natural history of HCV infection

(2013) Behzad Hajarizadeh et al.   Nature Reviews Gastroenterology & Hepatology

Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis

(2012) Rositsa B. Dimova et al.   CLINICAL INFECTIOUS DISEASES